Livnac-CR Tablet contains Aceclofenac 200 mg, a non-steroidal anti-inflammatory drug (NSAID) primarily indicated for the relief of pain and inflammation associated with musculoskeletal disorders such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Aceclofenac exerts its therapeutic effect by selectively inhibiting cyclooxygenase (COX), thereby reducing the synthesis of prostaglandins which are mediators of inflammation and pain. The controlled-release formulation of Livnac-CR allows for sustained drug release, enhancing patient compliance by reducing dosing frequency while maintaining effective plasma concentrations over an extended period. This tablet is beneficial in managing acute pain conditions including postoperative pain and dental pain. It is generally well tolerated; however, caution is advised in patients with a history of gastrointestinal ulcers, bleeding disorders, or renal impairment. Common adverse effects may include gastrointestinal discomfort, nausea, dizziness, and rash. Livnac-CR should be used under medical supervision, with dosage adjustments considered in elderly patients or those with hepatic or renal dysfunction. Concomitant use with other NSAIDs, anticoagulants, or corticosteroids should be avoided unless specifically directed by a healthcare professional to minimize the risk of adverse reactions. Regular monitoring is recommended during prolonged therapy to ensure safety and efficacy.